Product Reports Resources Pricing Login Book a demo
Power Law company profile

Cue Biopharma

Biotech & Life Sciences · Cambridge, United States · Founded 2015 · IPO 2018 Colt

Engineered a new class of injectable biologics that selectively activate the patient’s immune system directly in the patient’s body, without the need for ex vivo manipulation

Valuation
$25M
Market cap · May/2026
Revenue
$27M
Latest reported FY

Investors

1 investor on Cue Biopharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
MDB Capital Group

Global footprint

Where Cue Biopharma has talent and traffic

Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown
Web traffic by country
3.4K monthly visits
across markets
🇺🇸 United States61.8%
🇦🇹 Austria23.5%
🇮🇳 India14.7%
Top 3 markets shown

Market sentiment

What the market is saying about Cue Biopharma

An AI-synthesized read of the highest-engagement posts about Cue Biopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cue Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.